Overdiagnosis of bone fragility in the quest to prevent hip fracture

The BMJ

Volumn 350, Issue , 2015, Pages

  Järvinen, Teppo L N ^a   Michaëlsson, Karl ^b   Jokihaara, Jarkko ^c   Collins, Gary S ^d   Perry, Thomas L ^e   Mintzes, Barbara ^f   Musini, Vijaya ^e   Erviti, Juan ^g   Gorricho, Javier ^h   Wright, James M ^e   Sievänen, Harri ⁱ  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Oral Health Department   (Spain)

^h Government of Navarre   (Spain)

ⁱ UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE;

ARTICLE; BONE DENSITY; BONE FRAGILITY; COST EFFECTIVENESS ANALYSIS; DENSITOMETRY; DIAGNOSTIC ERROR; DRUG TARGETING; EVIDENCE BASED PRACTICE; HIP FRACTURE; HUMAN; OVERDIAGNOSIS; PATIENT HARM; PREDICTION; PREVALENCE; PRIORITY JOURNAL; EUROPE; HIP FRACTURES; INAPPROPRIATE PRESCRIBING; OSTEOPOROSIS; PATHOPHYSIOLOGY; RISK MANAGEMENT;

EUROPE; HIP FRACTURES; HUMANS; INAPPROPRIATE PRESCRIBING; OSTEOPOROSIS; RISK MANAGEMENT;

EID: 84937596958     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2088     Document Type: Article

References (61)

1. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8:136.
2. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417-27.
3. Järvinen TL, Kannus P. Osteoporosis and vertebral fractures: a newly discovered epidemic or just an example of overdiagnosis and disease mongering? BMJ 2011;343:d5040.
4. Kherad M, Rosengren BE, Hasserius R, et al. There is low clinical relevance of a prevalent vertebral fracture in old men-the MrOs Sweden Study. Spine J 2015;15:281-9.
5. Alonso-Coello P, Garcia-Franco AL, Guyatt G, et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 2008;336:126-9.
6. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81.
7. Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006;38:694-700.
8. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-411.
9. Jarvinen TL, Jokihaara J, Guy P, et al. Conflicts at the heart of the FRAX tool. CMAJ 2014;186:165-7.
10. Collins GS, Michaelsson K. Fracture risk assessment: state of the art, methodologically unsound, or poorly reported? Curr Osteoporos Rep 2012;10:199-207.
11. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J Bone Miner Res 2009;24:675-80.
12. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19(10):1395-408.
13. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013;75:392-6.
14. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18:1947-54.
15. Jarvinen TL, Sievanen H, Khan KM, et al. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008;336:124-6.
16. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000;27:585-90.
17. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
18. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003;348:42-9.
19. Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997;337:1279-84.
20. Wagner H, Melhus H, Gedeborg R, et al. Simply ask them about their balance-future fracture risk in a nationwide cohort study of twins. Am J Epidemiol 2009;169:143-9.
21. Sievanen H, Kannus P, Jarvinen TL. Bone quality: an empty term. PLoS Med 2007;4:e27.
22. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94.
23. Herndon MB, Schwartz LM, Woloshin S, et al. Implications of expanding disease definitions: the case of osteoporosis. Health Aff 2007;26:1702-11.
24. Poole KE, Compston JE. Bisphosphonates in the treatment of osteoporosis. BMJ 2012;344:e3211.
25. Musini VM, Bassett KL, Wright JM. A systematic review of the efficacy of bisphosphonates. Ther Lett 2011;83 (Sep-Oct):1-2.
26. European Medicines Agency. Scientific discussion: Aclasta EMEA-H-595-II-10-AR. www. ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion-Variation/human/000595/WC500020937.pdf.
27. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
28. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
29. Boonen S, Black DM, Colon-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-9.
30. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015 Apr 13. [Epub ahead of print.]
31. Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. 9 Sep 2011. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf.
32. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med 2012;366:2048-51.
33. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
34. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.
35. European Medicines Agency. EMEA/H/C/001120. Prolia (denosumab). European public assessment report, scientific discussion. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001120/WC500093529.pdf.
36. Food and Drug Administration. Statistical Review of Protocol 20090502. Prolia (denosumab). 29 Apr 2010. www.accessdata.fda.gov/drugsatfda-docs/nda/2010/125320s000StatR.pdf.
37. Group D. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:b5463.
38. Bolland MJ, Grey A, Gamble GD, et al. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014;2:307-20.
39. Korhonen N, Niemi S, Parkkari J, et al. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. Osteoporos Int 2013;24:1599-603.
40. Ballane G, Cauley JA, Luckey MM, et al. Secular trends in hip fractures worldwide: opposing trends East versus West. J Bone Miner Res 2014;29:1745-55.
41. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010;95:5258-65.
42. Kannus P, Niemi S, Parkkari J, et al. Why is the age-standardized incidence of low-trauma fractures rising in many elderly populations? J Bone Miner Res 2002;17:1363-7.
43. Feldstein AC, Weycker D, Nichols GA, et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009;44:153-9.
44. Crilly RG, Kloseck M, Chesworth B, et al. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces. Osteoporos Int 2014;25:205-10.
45. Jarvinen TL, Sievanen H, Kannus P, et al. The true cost of pharmacological disease prevention. BMJ 2011;342:d2175.
46. Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19:437-47.
47. El-Khoury F, Cassou B, Charles MA, et al. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:f6234.
48. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002;288:2300-6.
49. Michaelsson K, Olofsson H, Jensevik K, et al. Leisure physical activity and the risk of fracture in men. PLoS Med 2007;4:e199.
50. Olofsson H, Byberg L, Mohsen R, et al. Smoking and the risk of fracture in older men. J Bone Miner Res 2005;20:1208-15.
51. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005;16:155-62.
52. Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. BMJ 1991;303:453-9.
53. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med 1992;116:990-5.
54. Reid IR. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skelet Radiol 2011;40:1191-6.
55. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23.
56. Ulmner M, Jarnbring F, Torring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 2014;72:76-82.
57. Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014;371:974-6.
58. Aspenberg P. Denosumab and atypical femoral fractures. Acta Orthopaed 2014;85:1.
59. Reid IR. Should we prescribe calcium supplements for osteoporosis prevention? J Bone Metab 2014;21:21-8.
60. Reid IR, Bolland MJ. Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues? Osteoporos Int 2014;25:2347-57.
61. Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.